Symbols

INVA

Innoviva·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 6

Bearish signal 0

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

Significant Net Income Growth

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About INVA

Innoviva, Inc.

A company that develops small molecule drugs for the treatment of respiratory diseases

Industry

Pharmaceutical

Established Date

Listing Date

10/05/2004

Exchange

NASDAQ Stock Exchange

Full-time Employees

127

Fiscal Year Ends

12-31

Website

www.inva.com

Security Type

Common stock

Office address

1350 Old Bayshore Highway, Suite 400, Burlingame, CA 94010

Business

Introduction

Innoviva, Inc., was incorporated in Delaware in November 1996 as Advanced Pharmaceuticals Inc. The company began operations in May 1997. The Company changed its name to Innoviva on January 7, 2006 and is a biopharmaceutical company with a portfolio of internally discovered product candidates and strategic collaborations with pharmaceutical companies. The company focuses on the discovery, development and sales of small molecule drugs for use in many medical fields, including respiratory diseases, bacterial infections, and central nervous system diseases. Its strategy focuses on discovering, developing and selling efficient, convenient, tolerable and safe medicines. The company has its own proprietary approach, combining chemistry and biology, using its knowledge in multivalent to discover new product candidates.

Company Financials

EPS

INVA has released its 2025 Q3 earnings. EPS was reported at 1.08, versus the expected 0.38, beating expectations. The chart below visualizes how INVA has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

INVA has released its 2025 Q3 earnings report, with revenue of 107.80M, reflecting a YoY change of 20.44%, and net profit of 89.91M, showing a YoY change of 7312.04%. The Sankey diagram below clearly presents INVA's revenue sources and cost distribution.